Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from enGene Holdings ( (ENGN) ) is now available.
enGene reported first-quarter 2026 results showing cash, cash equivalents and marketable securities of $312.5 million, a runway the company expects will extend into the second half of 2028. The company also expanded its non-dilutive debt facility with Hercules Capital to up to $125 million and recently completed a $140.1 million public equity offering, bolstering financial flexibility to advance its lead bladder cancer candidate.
enGene highlighted encouraging preliminary data from the pivotal cohort of its LEGEND trial of detalimogene voraplasmid in high-risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with complete response rates above 60% at certain time points and a generally favorable tolerability profile. The company plans a LEGEND data update at a spring 2026 medical conference, expects 12-month response data and a Biologics License Application filing in the second half of 2026, and is working with the FDA under RMAT and CDRP programs to support potential U.S. approval and a possible commercial launch in 2027.
enGene’s inclusion in the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot program underscores regulators’ focus on enabling timely access to promising therapies and may streamline manufacturing readiness for detalimogene. Combined with its strengthened balance sheet and access to debt capital, these regulatory and clinical milestones position enGene to compete aggressively in the emerging treatment landscape for BCG-unresponsive bladder cancer and could be significant for investors and patients if late-stage results and approvals materialize.
The most recent analyst rating on (ENGN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
The score is held down primarily by weak financial performance (no revenue, large operating losses, and significant cash burn). Technicals are supportive due to a strong uptrend, but momentum appears overextended. The recent $130M financing improves funding runway, partially offsetting the weak fundamentals, while valuation remains constrained by a negative P/E and no dividend support.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage genetic medicines company developing non-viral gene therapies, with a lead program, detalimogene voraplasmid, targeting high-risk, Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. The company is focused on advancing detalimogene through late-stage clinical development and preparing for potential commercialization in the U.S. bladder cancer market.
Average Trading Volume: 314,488
Technical Sentiment Signal: Buy
Current Market Cap: $581.5M
See more insights into ENGN stock on TipRanks’ Stock Analysis page.